News

A ‘Miracle’ HIV Drug May Not Reach the Women Who Need It Most
Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...
Fierce Pharma9h
Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch
Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...
BioSpace12h
Gilead’s PrEP Launch Full Speed Ahead, Despite Macro Pressures on HIV Space
Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Herbs and hope in HIV crisis
IN a sunlit shack on the outskirts of Lesotho's capital Maseru, 34-year-old Lieketseng Lucia Tjatji sits under a black cloth ...
NEXTpittsburgh9h
Portraits of Pride: Dr. Ken Ho supports Pittsburgh’s LGBTQ+ community any way he can
No matter where you find him, Dr. Ho is taking a leadership role and working to make spaces in Pittsburgh safer and more ...
Investor's Business Daily on MSN4h
Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.
Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.